STOCK TITAN
  1. Home
  2. News
  3. COSM
  4. Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
earnings
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) reported Q1 2025 results showing significant improvement in profitability metrics despite revenue decline. Revenue decreased 5.98% to $13.71M, while gross profit surged 53.70% to $2.05M. The company achieved notable improvements in operational efficiency with gross margin expanding by 581 basis points to 14.95%. Operating expenses declined 9.05% to $2.88M through strategic cost reductions. The company returned to profitability on an adjusted basis, with Adjusted EBITDA of $0.37M (up 157.8%) and Adjusted Net Income of $0.28M (up 139.4%). Operating cash burn improved dramatically, decreasing 94.5% to -$0.19M. The balance sheet showed strength with total assets increasing 5.3% to $57.2M and stockholders' equity rising by $1.42M. CEO Greg Siokas demonstrated confidence by personally investing over $1.3M in company shares.
Cosmos Health (NASDAQ:COSM) ha riportato i risultati del primo trimestre 2025 mostrando un significativo miglioramento nei parametri di redditività nonostante una diminuzione dei ricavi. I ricavi sono diminuiti del 5,98% a 13,71 milioni di dollari, mentre il margine lordo è aumentato del 53,70% raggiungendo 2,05 milioni di dollari. L'azienda ha ottenuto notevoli miglioramenti nell'efficienza operativa con un'espansione del margine lordo di 581 punti base al 14,95%. Le spese operative sono diminuite del 9,05% a 2,88 milioni di dollari grazie a riduzioni strategiche dei costi. L'azienda è tornata a essere redditizia su base rettificata, con un EBITDA rettificato di 0,37 milioni di dollari (in aumento del 157,8%) e un utile netto rettificato di 0,28 milioni di dollari (in crescita del 139,4%). Il consumo di cassa operativo è migliorato drasticamente, riducendosi del 94,5% a -0,19 milioni di dollari. Lo stato patrimoniale ha mostrato solidità con un aumento del totale attivo del 5,3% a 57,2 milioni di dollari e un incremento del patrimonio netto degli azionisti di 1,42 milioni di dollari. Il CEO Greg Siokas ha dimostrato fiducia investendo personalmente oltre 1,3 milioni di dollari in azioni della società.
Cosmos Health (NASDAQ:COSM) reportó los resultados del primer trimestre de 2025 mostrando una mejora significativa en los indicadores de rentabilidad a pesar de una disminución en los ingresos. Los ingresos disminuyeron un 5,98% hasta 13,71 millones de dólares, mientras que la utilidad bruta aumentó un 53,70% alcanzando 2,05 millones de dólares. La compañía logró mejoras notables en la eficiencia operativa con un margen bruto que se expandió 581 puntos básicos hasta el 14,95%. Los gastos operativos disminuyeron un 9,05% hasta 2,88 millones de dólares gracias a reducciones estratégicas de costos. La empresa volvió a la rentabilidad en base ajustada, con un EBITDA ajustado de 0,37 millones de dólares (un aumento del 157,8%) y un Ingreso Neto Ajustado de 0,28 millones de dólares (un aumento del 139,4%). La quema de efectivo operativo mejoró drásticamente, reduciéndose un 94,5% a -0,19 millones de dólares. El balance mostró fortaleza con un aumento del total de activos del 5,3% hasta 57,2 millones de dólares y un incremento del patrimonio neto de los accionistas de 1,42 millones de dólares. El CEO Greg Siokas mostró confianza al invertir personalmente más de 1,3 millones de dólares en acciones de la compañía.
Cosmos Health (NASDAQ:COSM)는 2025년 1분기 실적을 발표하며 매출 감소에도 불구하고 수익성 지표가 크게 개선되었음을 보여주었습니다. 매출은 5.98% 감소한 1,371만 달러를 기록했으나, 총이익은 53.70% 증가한 205만 달러에 달했습니다. 회사는 총마진이 581 베이시스 포인트 확대되어 14.95%를 기록하는 등 운영 효율성에서 눈에 띄는 개선을 이루었습니다. 전략적인 비용 절감으로 영업비용은 9.05% 감소한 288만 달러를 기록했습니다. 조정 기준으로 회사는 수익성으로 돌아섰으며, 조정 EBITDA는 37만 달러로 157.8% 증가, 조정 순이익은 28만 달러로 139.4% 증가했습니다. 영업 현금 소진은 크게 개선되어 94.5% 감소한 -19만 달러를 기록했습니다. 대차대조표는 총자산이 5.3% 증가한 5,720만 달러, 주주지분이 142만 달러 증가하며 견고함을 보였습니다. CEO Greg Siokas는 회사 주식에 130만 달러 이상을 개인 투자하며 자신감을 나타냈습니다.
Cosmos Health (NASDAQ:COSM) a publié ses résultats du premier trimestre 2025, montrant une amélioration significative des indicateurs de rentabilité malgré une baisse du chiffre d'affaires. Le chiffre d'affaires a diminué de 5,98 % pour s'établir à 13,71 millions de dollars, tandis que le bénéfice brut a augmenté de 53,70 % pour atteindre 2,05 millions de dollars. La société a réalisé des améliorations notables en efficacité opérationnelle avec une marge brute en hausse de 581 points de base à 14,95 %. Les charges d'exploitation ont diminué de 9,05 % pour atteindre 2,88 millions de dollars grâce à des réductions stratégiques des coûts. La société est redevenue rentable sur une base ajustée, avec un EBITDA ajusté de 0,37 million de dollars (en hausse de 157,8 %) et un résultat net ajusté de 0,28 million de dollars (en hausse de 139,4 %). La consommation de trésorerie opérationnelle s'est nettement améliorée, diminuant de 94,5 % à -0,19 million de dollars. Le bilan a montré sa solidité avec une augmentation des actifs totaux de 5,3 % à 57,2 millions de dollars et une hausse des capitaux propres de 1,42 million de dollars. Le PDG Greg Siokas a fait preuve de confiance en investissant personnellement plus de 1,3 million de dollars dans les actions de la société.
Cosmos Health (NASDAQ:COSM) veröffentlichte die Ergebnisse für das erste Quartal 2025 und zeigte trotz eines Umsatzrückgangs eine deutliche Verbesserung der Profitabilitätskennzahlen. Der Umsatz sank um 5,98 % auf 13,71 Mio. USD, während der Bruttogewinn um 53,70 % auf 2,05 Mio. USD stieg. Das Unternehmen erzielte bemerkenswerte Verbesserungen in der operativen Effizienz mit einer Bruttomarge, die sich um 581 Basispunkte auf 14,95 % erhöhte. Die Betriebskosten sanken durch strategische Kostensenkungen um 9,05 % auf 2,88 Mio. USD. Auf bereinigter Basis kehrte das Unternehmen in die Profitabilität zurück, mit einem bereinigten EBITDA von 0,37 Mio. USD (plus 157,8 %) und einem bereinigten Nettogewinn von 0,28 Mio. USD (plus 139,4 %). Der operative Cashburn verbesserte sich drastisch und verringerte sich um 94,5 % auf -0,19 Mio. USD. Die Bilanz zeigte Stärke mit einem Anstieg der Gesamtvermögenswerte um 5,3 % auf 57,2 Mio. USD und einem Anstieg des Eigenkapitals um 1,42 Mio. USD. CEO Greg Siokas zeigte Vertrauen, indem er persönlich über 1,3 Mio. USD in Unternehmensanteile investierte.
Positive
  • Gross profit increased 53.70% to $2.05M with margin expansion of 581 basis points
  • Achieved profitability with Adjusted EBITDA of $0.37M and Adjusted Net Income of $0.28M
  • Operating cash burn improved 94.5%, reducing from -$3.41M to -$0.19M
  • Total assets increased 5.3% to $57.2M with stockholders' equity growth
  • CEO demonstrated confidence through $1.3M personal investment in shares
Negative
  • Revenue declined 5.98% to $13.71M year-over-year
  • GAAP Net loss of $0.82M, though improved from prior year
  • Total liabilities increased 4.9% to $31.24M
  • Increased lines of credit and notes payable

Insights

Cosmos Health shows turnaround with 54% gross profit growth and near-breakeven cash flow despite revenue decline; operating improvements driving profitability.

Cosmos Health's Q1 2025 results reveal a meaningful business transformation underway, with the company pivoting from growth-at-all-costs to profitability. While revenue declined 6% to $13.71M, gross profit jumped 54% to $2.05M, demonstrating the effectiveness of management's strategic shift toward higher-margin products and operational efficiency.

The gross margin expansion of 581 basis points to 14.95% represents substantial improvement in unit economics. This wasn't achieved through financial engineering but through fundamental business restructuring: shifting product mix toward proprietary brands, reducing promotional spending by 83.78%, and realizing synergies at Cana Laboratories.

Most impressive is the 94.5% reduction in operating cash burn to just $186K, putting Cosmos at the cusp of cash flow breakeven – the true inflection point for any turnaround story. The company achieved this while maintaining a reasonable balance sheet with a 54.6% liabilities-to-assets ratio.

Segment analysis shows wholesale logistics contributing $1.18M in gross profit, while owned brands and manufacturing delivered $0.87M. The company achieved adjusted EBITDA of $373K and adjusted net income of $277K, marking a substantial improvement from losses in both metrics last year.

The reconciliation of non-GAAP metrics reveals some complexity in the financial structure with significant stock-based compensation ($557K), non-recurring items, and various financial adjustments. However, the core operating metrics show genuine improvement in the underlying business fundamentals.

CEO Greg Siokas's increased personal investment of $1.3M since December 2024 represents meaningful skin-in-the-game and signals confidence in the turnaround strategy. The company appears to be successfully executing its transformation from a low-margin distributor to a higher-margin manufacturer of proprietary healthcare products.

CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025.

First Quarter 2025 Financial Highlights

Income Statement
Cosmos Health delivered solid results in Q1 2025, highlighted by a significant increase in gross profit and positive performance on both an Adjusted EBITDA and Adjusted Net Income basis, reflecting a meaningful turnaround in bottom-line performance.

  • Revenue for Q1 2025 was $13.71 million, a decrease of 5.98% from $14.58 million in Q1 2024, primarily reflecting the Company’s strategic shift toward higher-margin focus areas and a disciplined reduction of promotional-dependent activities.
  • Gross profit increased by 53.70% to $2.05 million, up from $1.33 million in the prior-year period, driven by an improved product mix and operational leverage. Segment contributions were as follows:
    • Wholesale logistics distribution: $1.18 million
    • Owned nutraceuticals/pharmaceuticals and manufacturing: $0.87 million
  • Gross margin expanded by 581 basis points to 14.95%, compared to 9.14% in Q1 2024, reflecting a greater focus on higher-margin segments, including contract manufacturing and proprietary brands, as well as operational synergies realized at Cana Laboratories.
  • Total operating expenses declined by 9.05% to $2.88 million, compared to $3.17 million in Q1 2024, reflecting:
    • 17.34% reduction in salaries and wages, driven by efficiency initiatives
    • 83.78% decline in sales and marketing expenses, due to a strategic reduction in promotional spend
    • 14.46% decrease in general and administrative expenses, adjusted for non-cash items
  • Net loss narrowed by 56.17% to $0.82 million, down from $1.87 million in the prior-year period. The loss was primarily attributable to costs related to the Company’s Nasdaq U.S. listing.

Return to Profitability
On an adjusted basis, Cosmos Health delivered profitable results in both EBITDA and Net Income, driven by improved gross profitability and disciplined cost management.

  • Adjusted EBITDA increased by 157.8% to $0.37 million, compared to a loss of $0.64 million in Q1 2024.
  • Adjusted Net Income improved by 139.4% to $0.28 million, versus a loss of $0.71 million in the prior-year period.

Key contributors to this performance were the Company’s wholesale logistics segment (CosmoFarm) and its owned nutraceutical and pharmaceutical products portfolio, including Sky Premium Life®, which delivered strong results.

Balance Sheet
Stockholders’ equity increased by $1.42 million, while the liabilities-to-assets ratio remained a modest 54.6%, reflecting continued financial discipline.

  • Total assets increased by 5.3% to $57.2 million, up from $54.3 million as of December 31, 2024, reflecting a diversified asset base with enhanced liquidity, a strong inventory position, and a solid real estate and intellectual property portfolio.
  • Total liabilities increased by 4.9% to $31.24 million as of March 31, 2025, up from $29.78 million at year-end 2024, primarily due to moderate increases in lines of credit and notes payable, while accounts payable and other current liabilities remained relatively stable.
  • Total stockholders’ and mezzanine equity increased by 5.8% to $25.95 million as of March 31, 2025, up from $24.53 million as of December 31, 2024.

Cash Flow Statement
Operating cash burn improved by 94.5% year-over-year, decreasing by $3.22 million to negative $0.19 million in Q1 2025 from negative $3.41 million in Q1 2024, primarily driven by improved working capital management, stronger accounts receivable collections, and lower prepaid expense outflows.

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated: “We are pleased with our strong first-quarter performance and the steady progress across multiple strategic areas. Gross profit and gross margins increased significantly, supported by an improved product mix and stronger operating leverage. Our continued focus on efficiency and disciplined cost management is yielding tangible results, as reflected in our return to profitability on both an Adjusted EBITDA and Adjusted Net Income basis.

Importantly, we are approaching a key milestone, having substantially reduced our operating cash burn and moving closer to operational cash flow breakeven. Moreover, we ended the quarter with higher stockholders’ equity and improved liquidity, including an increased cash balance. Our balance sheet remains prudent, underpinned by modest leverage and a diversified asset base.

Operationally, we continue to advance strategic initiatives across the group. Our R&D pipeline is evolving, with multiple projects underway, including our CCX0722 weight management solution which has entered its final development phase and is progressing toward launch. We are also scaling our high-margin contract manufacturing segment through new long-term agreements, while expanding the global footprint of Sky Premium Life, our flagship nutraceutical brand. In parallel, we are growing our C-Scrub antiseptics line, including continued progress in the lucrative UK market.

Finally, I want to reaffirm my personal commitment to Cosmos. Since December 20, 2024, I have increased my personal shareholding by over 2.7 million shares, representing an investment of more than $1.3 million, which reflects my strong confidence in the Company’s strategy and long-term growth potential.”

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
 
 Three Months Ended March 31,
 2025 2024 
(in $)  
GAAP - Figures  
REVENUE13,712,528 14,584,473 
GROSS PROFIT2,049,799 1,333,626 
TOTAL OPERATING EXPENSES(2,882,944) (3,169,734) 
GAIN (LOSS) FROM OPERATIONS(833,145) (1,836,108) 
TOTAL OTHER INCOME (EXPENSE), NET15,048 (30,582) 
NET GAIN (LOSS)(818,097) (1,866,690) 
   
NON-GAAP Figures*  
ADJUSTED EBITDA373,119 (644,048) 
ADJUSTED NET INCOME (LOSS)277,338 (706,955) 

(*) See "Definitions of Non-GAAP Measures" and "Reconciliation of Non-GAAP Measures" sections herein for an explanation and reconciliations of non-GAAP measures used throughout this release.

Definitions of Non-GAAP Measures

We collect and analyze operating and financial data to evaluate the health of our business and assess our performance. In addition to Revenue, Income (Loss) from Operations and Net Income (Loss) under GAAP, we use: EBITDA, Adjusted EBITDA, and Adjusted Net Income (Loss). We have included these non-GAAP financial measures because they are key measures used by our management to evaluate our operating performance. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. Our calculation of these non-GAAP financial measures may differ from similarly titled non-GAAP measures, if any, reported by our peer companies. These non-GAAP financial measures should not be considered in isolation from, or as substitutes for, financial information prepared in accordance with GAAP.

Adjusted EBITDA

We define Adjusted EBITDA as Income (Loss) before Income Taxes, excluding (i) depreciation and amortization expense, (ii) interest income (expense), (iii) non-cash interest expense, (iv) stock-based compensation expense, (v) non-recurring and extraordinary items (vi) other income (expense), net, (vii) gain (loss) on equity investments, net, (viii) gain on extinguishment of debt, (ix) change in fair value of derivative liability (x) foreign currency transaction, net, and (xi) prior years bad debt allowances.

We have included Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans, and make strategic decisions. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and non-recurring and extraordinary items.

Adjusted EBITDA has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP.

Adjusted Net Income (Loss)

We define Adjusted Net Income (Loss) as Adjusted EBITDA (see above) adding provision for income taxes and deducting interest expense.

Adjusted Net Income has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP.

Reconciliation of Non-GAAP Measures

Adjusted EBITDA & Adjusted Net Income (Loss)

The following table presents reconciliations of Adjusted EBITDA & Adjusted Net Income (Loss) to the most directly comparable GAAP financial measure for each of the periods indicated.

 Three Months Ended March 31,
 2025 2024 
(in $)  
INCOME (LOSS) BEFORE INCOME TAXES(818,097) (1,866,690) 
Adjustments (add back):  
Depreciation and amortization expense320,439 319,787 
Interest (income) / expense, net95,781 62,907 
EBITDA(401,877) (1,483,996) 
Non-recurring and extraordinary items135,621 532,078 
Stock based compensation556,611 340,194 
Other income (expense), net261,730 (191,824) 
Gain (loss) on equity investments, net(3,142) (1,755) 
Gain on extinguishment of debt(175,824) 161,254 
ADJUSTED EBITDA373,119 (644,048) 
Interest income / (expense), net(95,781) (62,907) 
ADJUSTED NET INCOME277,338 (706,955) 


CONDENSED CONSOLIDATED BALANCE SHEET DATA
 
 March 31, 2025
Unaudited		December 31, 2024
Audited		September 30, 2024
Unaudited
(in $)   
ASSETS   
Cash & cash equivalents742,881315,1053,314,845
Inventory4,736,2224,355,3654,885,015
Accounts receivable, prepaid expenses and other current assets20,930,78019,618,93227,101,314
Property and equipment, net10,016,0689,689,50510,575,928
Goodwill and intangible assets, net7,802,5297,756,5347,746,761
Loans receivable7,238,4946,946,7497,398,180
Other noncurrent assets5,724,9705,629,7023,497,939
TOTAL ASSETS57,191,94454,311,89264,519,982
    
LIABILITIES AND STOCKHOLDERS' EQUITY   
Accounts payable and accrued expenses12,542,70812,648,88212,818,143
Other current liabilities3,963,1673,564,5694,769,933
Lines of credit7,305,3776,985,0525,989,425
Notes payable4,863,2754,119,4714,279,340
Other non-current and finance/lease liabilities2,565,7052,460,9901,686,542
Stockholders' and mezzanine equity25,951,71224,532,92934,976,599
TOTAL LIABILITIES AND STOCKHOLDERS'/MEZZANINE EQUITY57,191,94454,311,89364,519,982
    


CONDENSED CONSOLIDATED CASH FLOW DATA
 
  Three Months Ended March 31,
(in $) 2025
Unaudited		 2024
Audited
NET CASH USED IN OPERATING ACTIVITIES (186,316)  (3,412,103) 
NET CASH USED IN INVESTING ACTIVITIES (7,069)  126,454 
NET CASH PROVIDED BY FINANCING ACTIVITIES 560,862  206,942 
     
CASH AT BEGINNING OF YEAR 315,105  3,833,195 
CASH AT END OF YEAR 742,881  865,099 
       


About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653


FAQ

What were Cosmos Health's (COSM) Q1 2025 financial results?

Cosmos Health reported Q1 2025 revenue of $13.71M (-5.98% YoY), gross profit of $2.05M (+53.70%), Adjusted EBITDA of $0.37M, and Adjusted Net Income of $0.28M. Operating cash burn improved 94.5% to -$0.19M.

How did COSM's profitability metrics improve in Q1 2025?

COSM achieved profitability on an adjusted basis with Adjusted EBITDA of $0.37M (up 157.8%) and Adjusted Net Income of $0.28M (up 139.4%). Gross margin expanded 581 basis points to 14.95%.

What cost reduction measures did Cosmos Health implement in Q1 2025?

COSM reduced operating expenses by 9.05% through 17.34% reduction in salaries, 83.78% decline in sales/marketing expenses, and 14.46% decrease in general administrative expenses.

How much did COSM's CEO invest in company shares?

CEO Greg Siokas increased his personal shareholding by over 2.7 million shares, representing an investment of more than $1.3 million since December 20, 2024.

What is Cosmos Health's current balance sheet position?

As of March 31, 2025, COSM had total assets of $57.2M (+5.3%), total liabilities of $31.24M, and stockholders' equity of $25.95M (+5.8% from December 2024).
Stock COSM logo
Cosmos Health Inc.

NASDAQ:COSM

COSM Rankings

#5711 Ranked by Market Cap
N/A Ranked by Dividends

COSM Latest News

May 7, 2025
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
May 6, 2025
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
Apr 30, 2025
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
Apr 16, 2025
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
Apr 9, 2025
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

COSM Stock Data

11.51M
18.92M
29.66%
6.97%
3.46%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
THESSALONIKI